|
1
|
Ma H, Jiang Q, Chuang-Stein C, Evans SR, He W, Quartey G, Scott J, Wen S, Arani R. Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product. Stat Biopharm Res 2016. [DOI: 10.1080/19466315.2016.1234974] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Haijun Ma
- Amgen Inc., Global Biostatistics and Epidemiology, Thousand Oaks, CA, USA
| | - Qi Jiang
- Amgen Inc., Global Biostatistics and Epidemiology, Thousand Oaks, CA, USA
| | | | - Scott R. Evans
- Biostatistics, Harvard School of Public Health, Boston, MA, USA
| | - Weili He
- Merck & Co., Inc., Kenilworth, NJ, USA
| | | | - John Scott
- Center for Biologics Evaluation and Research, FDA, Silver Spring, MD, USA
| | - Shihua Wen
- Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
| | - Ramin Arani
- AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA
| |
Collapse
|